Navigation Links
CNS Response, Inc. Names William E. Bunney, Jr., MD to Scientific Advisory Board
Date:5/5/2008

COSTA MESA, Calif., May 5 /PRNewswire-FirstCall/ -- CNS Response, Inc. (OTC Bulletin Board: CNSO) announced today that it has appointed William E. Bunney, Jr., MD to its Scientific Advisory Board. Dr. Bunney is Senior Associate Dean for Research and Distinguished Professor, Department of Psychiatry and Human Behavior, School of Medicine, University of California, Irvine.

Len Brandt, Chairman and CEO of CNS Response, reported, "Considering Dr. Bunney's distinguished career and his position as a thought leader in psychiatry, we are honored that he has accepted a position on our Scientific Advisory Board. His informal counsel has been very valuable to CNS Response during the past year. I am certain that Dr. Bunney's continued input will benefit CNS Response's mission to provide physiological guidance to treatment."

In addition to his position at the University of California, Irvine, Dr. Bunney has held key appointments with several prominent government institutions and research organizations focused on mental health and behavioral sciences-related issues. Among his affiliations, Dr. Bunney currently serves on the Scientific Advisory Boards of the Harvard International Brain Repository and the World Health Organization (WHO) Expert Panel on Mental Health, was previously the Director of the Federal Treatment, Education and Research Endeavor for Narcotic Addiction and Drug Abuse with the National Institutes of Health, and was elected to the Institute of Medicine of the National Academy of Sciences where he was designated a Lifetime National Associate. Dr. Bunney has also served as President of four research organizations: American College of Neuropsychopharmacology, CINP, West Coast College of Biological Psychiatry, and Psychiatric Research Society.

Dr. Bunney received his M.D. from the University of Pennsylvania Medical School and completed his residency in Psychiatry at Yale University School of Medicine. He is the author of more than 390 scientific publications and the editor of seven books.

About CNS Response

CNS Response is a life-sciences data company whose patented system provides treatment guidance to psychiatrists and other physicians for patients with behavioral (mental or addictive) disorders. This technology allows CNS Response to create and provide simple reports ("rEEG(R) Reports") that specifically guide physicians to treatment strategies based on the patient's own physiology.

rEEG(R) utilizes traditional electroencephalography (EEG) in conjunction with a normative database and a proprietary clinical (symptomatic) database to identify the following: (1) medication classes most likely to be needed; and (2) medications within these classes with the most probable treatment potential for each patient. Reports are provided to physicians in a relationship analogous to that of a reference laboratory. Prospective, retrospective and field studies of treatment-resistant patients have reported treatment success of 70% or greater in managed care, outpatient psychiatric and residential substance abuse clinical settings.

In addition to providing analytical support to physicians, CNS Response is also an aid to pharmaceutical developers, who can use rEEG to (1) stratify study populations to improve the success of FDA clinical trials; (2) provide insight on effective therapeutic dosing of investigational drugs; (3) identify additional indications for psychiatric medications; (4) provide insight into effective drug combinations; and (5) discover opportunities for decision analytics and support. In addition to these applications, CNS Response continues to investigate the use of rEEG analysis for development of proprietary pharmaceutical opportunities.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

Except for the historical information contained herein, the matters discussed are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements involve risks and uncertainties as set forth in the Company's filings with the Securities and Exchange Commission. These risks and uncertainties could cause actual results to differ materially from any forward-looking statements made herein.

Contacts:

Investor Relations:

Sara Ephraim

(646) 536-7002

sephraim@theruthgroup.com

Media:

Jason Rando / Jennifer Saunders

(646) 536-7033 / 7011

jrando@theruthgroup.com

jsaunders@theruthgroup.com


'/>"/>
SOURCE CNS Response, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. CNS Response, Inc: rEEG(R) Research to be Presented at 38th National Council Conference
2. CNS Response, Inc. Enters Agreement to Introduce rEEG(R) Platform to Managed Behavioral Health Organization
3. Bacterial toxin closes gate on immune response, Penn researchers discover
4. CNS Response, Inc. Names Henry T. Harbin, MD to Board of Directors
5. CNS Response, Inc. Modifies rEEG(SM) Trial Protocol for Treatment-Resistant Depression Study
6. CNS Response, Inc. Appoints George C. Carpenter IV to Position of President
7. AACN Names 2008 Circle of Excellence Award Recipients
8. Cosmetic Bootcamp Announces Record Attendance and Sponsorship and Names Members of Its Board of Advisors
9. PEMCOs Super-Long-Coffee-Order Contest Names Newest Winners
10. Ventas Names Chicago as Headquarters
11. SCA Names Andrew Hayek as New President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... Nashville, TN (PRWEB) , ... February 17, 2017 ... ... Services, Inc. (ISTS) brings its educational assistance management solution to the exhibit floor ... Convention Center in Orlando, Fla. , From Feb. 19–23, 2017, more than ...
(Date:2/17/2017)... ... 17, 2017 , ... Qualis Health, one of the nation's ... Annual DecisionHealth Platinum Awards in recognition of its innovative healthcare management programs that ... multiple award categories, highlighting four of the organization’s current programs:, ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... clinical operations executives and focusing on all facets of clinical trial planning and ... management , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth ...
(Date:2/17/2017)... , ... February 17, 2017 , ... Top neuroendocrine cancer ... Healing NET Foundation Summit from February 21 - 23 in Beaver Creek, CO. It ... This marks the Summit’s second year in Beaver Creek, hosting over 60 faculty members ...
(Date:2/16/2017)... (PRWEB) , ... February 17, 2017 , ... ... their experience can last long after their final treatments. Physician researchers at ... neuro-emotional technique (NET), a mind-body therapy, for efficacy in reducing symptoms of traumatic ...
Breaking Medicine News(10 mins):
(Date:2/17/2017)... February 17, 2017 On Thursday, ... 500 edged lower at the closing bell, while the ... the 20,000 benchmark. Moreover, five out of nine sectors ... consideration yesterday,s market sentiment, Stock-Callers.com assessed the following Medical ... PLC (NYSE: SNN ), ABIOMED Inc. (NASDAQ: ...
(Date:2/16/2017)... 2017 DaVita Inc. (NYSE: DVA ) ... 31, 2016. Net income attributable to DaVita ... was $158 million, or $0.80 per share and $880 million, ... income attributable to DaVita Inc. for the quarter and year ... was $192 million, or $0.98 per share, and $789 million, ...
(Date:2/16/2017)... Scripts (NASDAQ: ESRX ) was recognized today by Fortune ... Health Care: Pharmacy and Other Services category. "Express Scripts ... Companies," said Tim Wentworth , CEO and President, Express Scripts. ... 26,000 employees to make medicine more affordable and accessible for the ... ...
Breaking Medicine Technology: